ProteusONE
™
Compact proton therapy solution
Protons are Possible
www.iba-proteusone.com
IBAL01_1047 ProteusONE A4v15.indd 1
Some features are under development and are subject to review by competent authorities (FDA, Notified bodies, et al...)
22/09/11 11:47
PrOTON ThEraPY. a TrUE sUccEss iN caNcEr carE Proton therapy is used today to treat many cancers and is particularly appropriate in situations where treatment options are limited and conventional radiotherapy presents an unacceptable risk to the patient. These situations include eye or brain cancers, tumors close to the brain stem or spinal cord, prostate cancers, and pediatric cancers.
1 2
3
4 5
6
1. cENTral NErvOUs sYsTEM Adult Low and High Grade Gliomas Pediatric Gliomas Acoustic Neuromas · Recurrent or Unresectable Meningiomas · Recurrent or Unresectable Craniopharyngiomas Chordomas and Low Grade Chondrosarcomas Arteriovenous Malformations Medulloblastomas Pituitary Adenomas Posterior Fossa Tumors 2. EYE & OrbiT Uveal Melanomas Macular Degeneration Choroidal Melanomas Retinoblastomas Choroidal Metastases Orbital Rhabdomyosarcomas Choroidal Hemangiomas Optic Gliomas 3. hEaD & NEcK Paranasal Sinus Salivary Glands Carcinomas Nasopharynx · Primary and Recurrent Esophogeal Carcinomas Recurrent Carcinomas 4. ThOrax Non Small Cell Lung Carcinomas Breast Cancer Early Stage-Medically Inoperable Paraspinal Tumors Soft Tissue Sarcomas Lymphomas
For a general overview of the clinical aspects of proton therapy, refer to the following works: - “Proton and charged particle radiotherapy” by Thomas F. Delaney, Hanne M. Kooy - “Proton Therapy”, Series: Radiation Medicine Rounds Volume 1 Issue 3 by James M. Metz and Charles R. Thomas, Jr.
IBAL01_1047 ProteusONE A4v15.indd 2
5. gasTrOiNTEsTiNal MaligNaNciEs Oesophageal Carcinomas Reccurent Rectal Cancer Pancreatic Cancer Hepatocellular Carcinomas 6. PElvis Early Stage Prostate Carcinomas Locally Advanced Prostate Carcinomas Locally Advanced Cervix Carcinomas Pelvic Sarcomas Pediatric Malignancies Ewing’s Sarcomas Retroperitoneal Sarcomas Genicologic Carcinomas
22/09/11 11:48
ProteusONE
™
IBA ProteusONE ™ is a compact single-room proton therapy solution. It benefits from the latest technologies of ProteusPLUS ™ that have been developed over the years with top clinical institutions worldwide. ProteusONE ™ is designed to bridge the gap between conventional radiotherapy and proton therapy. ProteusONE ™ offers extended treatment solutions (IMPT, IGPT) enabling physicians to leverage completely on the clinical effectiveness offered by the proton beam precision. ProteusONE ™ has been inspired by everyday clinical practice. Its design enhances the patient experience by fostering a soothing environment while making the medical staff daily practice safer and easier. Finally ProteusONE ™ is the IBA response to make protons affordable. It is a proton therapy system that is smaller, more affordable, easier to install, easier to operate and ultimately easier to finance. With ProteusONE ™, protons are possible for more patients worldwide.
1 // iba ProteusONE
IBAL01_1047 ProteusONE A4v15.indd 1
™
22/09/11 11:48
iba ProteusONE // 2 ™
IBAL01_1047 ProteusONE A4v15.indd 2
22/09/11 11:48
Treating with
ProteusONE
™
IBA ProteusONE ™ is a compact singleroom proton therapy solution. It offers EXTENDED treatment solutions. This proton therapy solution offers treatment capabilities that will allow you to fully leverage the clinical effectiveness offered by proton beam precision. On the one hand, ProteusONE ™ proposes the Pencil Beam Scanning mode enabling the delivery of Intensity Modulated Proton Therapy (IMPT ) treatment plans.
Tr ea ti ng
w it h I M PT
De li ve ri ng t he be am to t ad apt iv he ne E I M AG ar E G es t m UI DE il D li PR mete OT ON r TH ERA PY
On the other hand, the latest imaging techniques are incorporated in ProteusONE ™ to enable adaptive Image Guided Proton Therapy (IGPT).
3 // iba ProteusONE
IBAL01_1047 ProteusONE A4v15.indd 3
™
22/09/11 11:48
Treating with Intensity modulated Proton Therapy ProteusONE ™ delivers the proton beam to the tumor using the Pencil Beam Scanning (PBS) modality. Thanks to its precision and its specificities, PBS enables Intensity Modulated Proton Therapy. This provides the ability to precisely target the tumor and control the intensity and spatial distribution of the dose with sub-millimetric precision. With ProteusONE ™ IMPT capabilities, you will have the ability to precisely sculpt the dose into the target tumor, reaching high levels of conformality and dose uniformity, even in complex-shaped tumors.
What is Pencil Beam Scanning (PBS)? PBS is a proton beam delivery mode. The proton beam is steered across the target volume, one layer at a time, pixel by pixel, to precisely match the shape of the tumor. This active scanning technique allows the physicians to modulate or change the intensity of the beam at any specific location in the target. PBS key advantages: — Thanks to its millimeter precision, PBS offers the ultimate capability of sculpting the dose with very high levels of conformality and dose uniformity, even in complex-shaped tumors. — It enables Intensity Modulated Proton Therapy (IMPT) as well as Single Field Uniform Dose (SFUD) deposition. — PBS is easy to operate and limits the use of patient specific devices. It delivers the smallest possible neutron dose to the patient as it does not use apertures or compensator devices. — Combined with the appropriate devices and treatment strategies, it is adequate to treat moving tumors.
iba ProteusONE // 4 ™
IBAL01_1047 ProteusONE A4v15.indd 4
22/09/11 11:48
delivering the beam to the nearest millimeter ProteusONE ™ brings together the most advanced techniques of Patient Positioning for Proton theraPy treatments, therefore enabling your treatment Procedures to leverage Proton beam Precision. the technology develoPed over the years by iba and its clinical Partners has Proven successful in delivering the Proton beam with sub-millimetric Precision.
220° Of TrEaTMENT frEEDOM iN ThE MOsT cOMPacT DEsigN EvEr DEvElOPED The IBA 220° Compact Gantry Treatment Room* combines the following advantages: — Uncompromised positioning treatment options provided by a continuouslyadjustable treatment angle combined with 6° freedom of movement offered by the patient positioner. All treatment angles can be achieved. — The most compact gantry design* ever developed for proton therapy, while still enabling easy patient access and noncoplanar treatments. — It enables advanced imaging technologies (Cone Beam Computed Tomography* (CBCT), Fluoroscopy, 2.5D Digital x-ray Imaging).
rObOTic PaTiENT POsiTiONiNg sYsTEM (rPPs) Positioning the patient with the utmost care while ensuring the precision of this position in the treatment environment is key to clinical effectiveness. The robot selected by IBA for the ProteusONE™ extends the treatment possibilities by allowing a wider treatment volume, 6° freedom of movement and noncoplanar treatment capabilities. ProteusONE ™ RPPS advantages include: — positioning with 6 axis of freedom including pitch and roll capacity; — capability for additional services such as water phantom handling or quality assurance tools coupling; — a greater extension of the arm in the treatment room, allowing further applications; — small footprint.
* CBCT and 220° Compact Gantry are ongoing developments. The marketing approval will be subject to review by competent authorities (FDA, Notified bodies,et al…)
5 // iba ProteusONE
IBAL01_1047 ProteusONE A4v15.indd 5
™
22/09/11 11:48
Towards adaptive IGPT… Proton therapy has always used imageguidance for patient positioning in order to meet the accuracy requirements set by the superior dose distribution of the Bragg peak. Thanks to ProteusONE ™ imaging solutions, you will have the ability to image the patient in order to provide the radiation oncologist with all relevant anatomical information that could lead to real IMAGEGUIDED Proton Therapy.
2.5D orthogonal x-ray and fluoroscopy In addition to automatic registering, 2.5D imaging and “in treatment” fluoroscopy will be made possible by two digital x-ray panels. Fluoroscopy is an imaging technique that produces real time x-ray video of body structures. The system enables the medical user to observe the position of the tumor and the treatment area during the treatment. It is particularly adapted to follow patient organs movements.
iba ProteusONE // 6 ™
IBAL01_1047 ProteusONE A4v15.indd 6
22/09/11 11:48
NEw cONE bEaM cOMPUTED TOMOgraPhY* Currently, two orthogonal x-ray projection images are used to compare the treatment position of the patient with the planned position. If Computed Tomography (CT) data can be directly acquired in the treatment room of the proton therapy system, it is possible to compare them with the CT images of the radiotherapy treatment planning system. This gives much more accurate results than the conventional orthogonal alignment system. Clinical users can then apply similar positioning and imaging protocols as those used in their IGRT practice.
IBA and its clinical partner are currently fi nalizing the development of a proton therapy system that accommodates CBCT* technology in the 220° Compact Gantry Treatment Room* design confi guration. The IBA solution brings the advantages of: — acquiring CBCT* image in room and in treatment position; — ensuring accurate patient positioning; — enabling the detection of anatomic modifi cations of the patient on the radiological path.
First images of an head phantom produced using FDK reconstruction of images acquired on IBA PT Gantry CBCT test bench (or prototype).
* CBCT and 220° Compact Gantry are ongoing developments. The marketing approval will be subject to review by competent authorities (FDA, Notified bodies, et al…)
7 // iba ProteusONE
IBAL01_1047 ProteusONE A4v15.indd 7
™
22/09/11 11:48
iba ProteusONE // 8 ™
IBAL01_1047 ProteusONE A4v15.indd 8
22/09/11 11:48
a design
i nspired by clinical care Working with clinicians and nurses in the development of proton therapy worldwide over the last 20 years has led the IBA team to understand that successful treatment does not only depend on proton beam physics.
vi ronment
hi ng p at ient en
Soot
OP TI M IZ ED
st af f
EX PE RI EN CE
ProteusONE ™ has been designed to enhance the patient experience by fostering a soothing environment. At the same time, all care has been taken to facilitate medical staff daily practice.
9 // iba ProteusONE
IBAL01_1047 ProteusONE A4v15.indd 9
™
22/09/11 11:48
Optimized staff experience
Open treatment enclosure*
In-room imaging control
The ProteusONE™ is designed with an open treatment enclosure*. It allows the physicians and nurses to have easy access to the patient in treatment position. This facilitates patient care and improves positioning procedures while allowing noncoplanar treatments.
In addition to treatment controls from the therapy control room, all imaging can be controlled from inside the treatment room for improved patient care, greater ease of use and efficient streamlining of positioning procedures.
Gantry Rolling Floor (GRF)
* CBCT and 220° Compact Gantry are ongoing developments. The marketing approval will be subject to review by competent authorities (FDA, Notified bodies, et al…)
Thanks to the highly original design of the GRF, the patient remains very accessible to the medical staff even though the gantry rotates around the isocenter (220°). The GRF ensures staff safety during clinical operations, allowing them to focus on their core tasks and patient wellbeing.
iba ProteusONE // 10 ™
IBAL01_1047 ProteusONE A4v15.indd 10
22/09/11 11:48
Soothing patient environment To design the ProteusONE ™ treatment room, IBA partnered with Philips Design’s expert team of designers who have a longstanding experience in the development of patient-friendly medical environments. This has led to a design that soothes patients undergoing treatment procedures. Natural materials and appeasing colors have been carefully selected to create a peaceful environment. In order to help the patient feel more comfortable, the room design offers some degree of personalization (eg. a music station has been incorporated).
11 // iba ProteusONE
IBAL01_1047 ProteusONE A4v15.indd 11
™
22/09/11 11:48
Proton therapy made affordable
Through the development of proton therapy projects worldwide with many different clinical institutions, the IBA team has learned that the biggest challenge is not developing leading-edge technology, nor convincing clinicians about the effectiveness of protons in oncology, but making this technology accessible to more patients worldwide. This is the challenge that IBA has taken on. ProteusONE ™ is our response; a proton therapy system that is smaller, more affordable, easier to install, easier to operate and ultimately easier to finance.
W hen si ze m atte W rs hen it come s to t ime and money
With ProteusONE ™, protons are possible for more patients worldwide.
iba ProteusONE // 12 ™
IBAL01_1047 ProteusONE A4v15.indd 12
22/09/11 11:48
When size matters… In many areas, size matters. This is particularly true in the medical context where every square foot is invaluable. There is a common belief that proton therapy is big, if not to say huge. It is therefore thought to be inaccessible for most institutions.
The IBA team is working relentlessly to prove this belief false. The result is the ProteusONE ™: a PT solution with a footprint the size of approximately two linac vaults.
When it comes to time and money… Bringing proton therapy to the community is a tough challenge for most oncology institutions, even though proton therapy has today gained worldwide recognition as a powerful cancer treatment modality.
medical community at a lower cost while optimizing the time to first patient. Those two factors contribute to create a proton therapy solution that is easier to develop and finance.
The success of a proton therapy project often comes down to issues related to time and money.
In addition, IBA is currently developing a partnership with financial institutions worldwide to provide ProteusONE ™ customers with simple and accessible leasing solutions.
With ProteusONE ™, IBA has made a breakthrough in terms of PT affordability. ProteusONE ™ brings proton therapy to the
13 // iba ProteusONE
IBAL01_1047 ProteusONE A4v15.indd 13
™
22/09/11 11:48
leading institutions have already chosen iba. Join them to develoP the future of cancer care together. sTaY fOcUsED ON PaTiENT carE, wE caN rUN ThE sYsTEM fOr YOU Our experience with more than half of the clinical proton therapy centers worldwide has led us to understand the worries and clinical complexities that arise when treating cancer. Our commitment is to ensure your clinical success by providing reliable tools with the highest availability possible (over 95% uptime). This will enable your institution to become a reference cancer center using the latest radiotherapy modality, proton therapy. To date, being part of the IBA proton therapy client network and benefi ting from our service organization experience has helped centers around the world to successfully deliver more than 300,000 fractions to cancer patients. Your team will be able to focus on the clinical aspects of cancer care while IBA’s team takes care of ensuring that your proton therapy system runs at top performance and meets the highest safety and reliability standards.
OPEraTiON aND MaiNTENaNcE sErvicEs iN a NUTshEll With more than 70 service professionals in three continents, you can have access to our qualifi ed fi eld support team at any time, day and night. In addition to personalized support, other key services are provided: — 24/7 remote support service, online or over the phone, is an important component to keep your equipment’s high uptime. — A team of IBA trained specialists will operate the system onsite to ensure the highest level of availability for clinical treatment. — In case of emergency, we can deliver spare parts the same day via our extensive spare parts worldwide network with hubs in America, Asia and Europe. — Because technology changes quickly, IBA develops both update and upgrade packages tailored to your center’s confi guration and training programs to increase your team’s effi ciency. NEw sErvicE fEaTUrEs iNclUDE: — Remote Service Connections to proton therapy accelerator systems; — Worldwide Computerized Maintenance Management Systems.
iba ProteusONE // 14 ™
IBAL01_1047 ProteusONE A4v15.indd 14
22/09/11 11:48
2 InDIAnA unIversIty heAlth Proton therAPy center Bloomington, IN, USA
rOOMs
Two gantry rooms. Treating since 2004
4
rOOMs
4 cDh Proton therAPy center, A Procure center Chicago, IL, USA
rOOMs
One gantry room, two inclined-beam rooms, one fixedbeam room. Treating since 2010
Procure Proton therAPy center Seattle, WA, USA
2 mAssAchusetts generAl hosPItAl Burr Proton therAPy center Boston, MA, USA
rOOMs
Cyclotron, Energy Selection System (ESS), two gantry rooms. Treating since 2001
2
rOOMs
rOOMs
rOOMs
New cyclotron connected to two existing fixedbeam rooms. Extension of the existing facility by one gantry room. Treating since 2009
In development. Expect to have four treatment rooms. Opening in 2013
4
2
centre De ProtonthÉrAPIe De I’InstItut curIe Paris (Orsay), France
4
BronowIce cyclotron center Kraków, Poland
rOOMs
Cyclotron, ESS, one research room, one fixed-beam room. Opening in 2013
2
rOOMs
4 feDerAl hIgh-tech meDIcAl center Dimitrovgrad, Russia, Europe
rOOMs
Cyclotron, two gantry treatment rooms, one dual beam treatment room and 1 eye treatment room. Opening in 2013
Procure Proton therAPy center In oklAhomA cIty Oklahoma City, OK, USA
3
rOOMs
First USA Proton Therapy facility in a private practice setting, one gantry room, two inclined-beam rooms, one fixed-beam room. Treating since 2009
2
5 hAmPton unIversIty Proton therAPy InstItute Hampton, VA, USA
rOOMs
4 unIversIty of florIDA Proton therAPy InstItute Jacksonville, FL, USA
2
rOOMs
rOOMs
wAnjIe Proton therAPy center Zibo, China Cyclotron, ESS, one gantry room, one fixed-beam room. Expandable by two additional gantry rooms. From project start to first patient treated in only three years. Treating since 2004
Cyclotron, ESS, three gantry rooms, one fixed-beam room. Treating 100 patients per day within two years of opening. Treating since 2006
In development. Expect to have four treatment rooms. Opening in 2013
nAtIonAl cAncer center Kashiwa, Japan Cyclotron, ESS, two gantry rooms. Developed in association with Sumitomo Heavy Industry, LTD. Treating since 1998
Cyclotron, ESS, four gantry rooms, one fixed-beam room. Fastest build to date for IBA and partners. Treating since 2010
4 Procure Proton therAPy center Princeton, NJ, USA
nAtIonAl cAncer center Ilsan, Korea Cyclotron, ESS, two gantry rooms, one fixed-beam room. Expandable by one gantry room. Treating since 2007
rOOMs
rOOMs
Cyclotron, ESS, three gantry rooms, one fixed-beam room. First Proton Therapy center based on a public-private partnership (PPP) model.
skAnDIonklInIken Uppsala, Sweden Cyclotron, ESS, two gantry rooms, one research room. Opening in 2013
westDeutsches ProtonentherAPIeZentrum essen (wPe) Essen, Germany
5
rOOMs
unIversIty of PennsylvAnIA heAlth system roBerts Proton therAPy center Philadelphia, PA, USA Cyclotron, ESS, four gantry rooms, one fixed-beam room, one research room. The largest Proton Therapy center project to date. Treating since 2009
3
rOOMs
AgenZIA ProvIncIAle Per lA ProtonterAPIA (AtreP) Trento, Italy Cyclotron, ESS, two gantry rooms and one fixed-beam room. First gantry-equipped Proton Therapy center in Italy. Opening in 2013
3
rOOMs
unIversItAtklInIkum cArl gustAv cArus Dresden, Germany Cyclotron, ESS, one gantry room, one research room. Opening in 2014
4 Proton therAPy center cZech s.r.o. Prague, Czech Republic
rOOMs
Cyclotron, ESS, three gantry rooms, one fixed-beam room. The first of its kind in eastern Europe. Opening in 2012
This map has been last updated in September 2011.
IBA has designed and installed the majority of clinically operating proton therapy centers in the world.
15 // iba ProteusONE
IBAL01_1047 ProteusONE A4v15.indd 15
™
22/09/11 11:48
Contact us Americas Toll-free: 1 877 IBA 4 PBT T +1 904 224 6100 Europe, Middle East and Africa T +32 10 203 342 F +32 10 475 923 Russia & CIS T/F +7 495 648 69 00 E-mail: info@iba-russia.ru Asia Pacific T +86 10 8080 9186 E-mail: info-pt@iba-group.com Visit us online at: www.iba-proteusone.com
iba ProteusONE // 16 ™
IBAL01_1047 ProteusONE A4v15.indd 16
22/09/11 11:48
While all care has been taken to ensure that the information contained in this publication is correct, we accept no responsibility for any inaccuracy and reserve the right to modify this information. Technical specifications are based on standard operating conditions and may be subject to variations. Pictures and illustrations are not contractual. ProteusONE ™ is the brand name of a new configuration of the Proteus 235 including some new developments subject to review by competent authorities before marketing. Empath is a registered trademark of IBA Particle Therapy. IBA, a Belgian company, is listed on the panEuropean stock exchange EURONEXT and its annual reports can be downloaded on the website: www.iba-worldwide.com. Published by IBA S.A., Chemin du Cyclotron, 3 1348 Louvain-la-Neuve, Belgium. This brochure is printed on ECF woodfree coated paper. It was produced with plants that comply with ISO 14001, the environmental management standard.
IBAL01_1047 ProteusONE A4v15.indd 17
22/09/11 11:48
IBA Group | 2011 | ProteusONE ™ 2011
IBA Particle Therapy With more than 25 years of experience, IBA is at the forefront of developing the technology and treatment facilities for delivering proton therapy to meet growing demands. IBA, the market leader, has designed and equipped the majority of clinically operating proton therapy centers around the world. At IBA, our expertise and knowledge cover all aspects of the process, from site selection to design, systems integration and maintenance, together with financing offerings and many other services. Our team of experts has unrivaled experience in designing, building, installing and operating proton therapy facilities. We do what it takes to help create the right proton therapy facility for you and your patients and help you stay on the leading edge of cancer treatment. Our goal is to ensure the highest equipment performance to keep you on time and on budget.
Visit us online at:
www.iba-proteusone.com
IBAL01_1047 ProteusONE A4v15.indd 18
22/09/11 11:48